Black Diamond Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a clinical-stage precision oncology company focused on the discovery and development of small molecule targeted therapies. The company is built around its proprietary "MasterKey" discovery platform, which is designed to identify and target structural classes of mutant oncoproteins rather than single, isolated mutations. This approach aims to address broad genetically defined patient populations, overcome resistance mechanisms, minimize wild-type mediated toxicities, and achieve brain penetration to treat central nervous system (CNS) disease. The company's lead clinical candidate is silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor. Silevertinib is currently being evaluated in Phase 2 clinical trials for EGFR-mutant non-small cell lung cancer (NSCLC) and newly diagnosed EGFRvIII-positive glioblastoma (GBM).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing silevertinib, a brain-penetrant fourth-generation EGFR MasterKey inhibitor, for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) and EGFR-altered glioblastoma (GBM).
Expected impact: Establish silevertinib as a best-in-class therapeutic option for rare oncology indications and secure a registrational pathway with the FDA.
Implementing workforce reductions and operational efficiencies to focus resources on the lead program silevertinib and extend the cash runway.
Expected impact: Extended the company's cash runway into the second half of 2028, providing financial stability to execute clinical trials.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Servier assumed responsibility for the development and global commercialization of BDTX-4933 across multiple indications, including NSCLC, allowing Black Diamond to focus resources on silevertinib.
Terms: Black Diamond received an upfront payment of $70 million in March 2025 and is eligible to receive up to $710 million in development and commercial sales milestone payments, plus tiered royalties on global net sales.